Influence of Immune Inflammation on Androgen Receptor Expression in Benign Prostatic Hyperplasia Tissue

Overview

Journal Asian J Androl

Specialty Urology

Date 2011 Dec 14

PMID 22157983

Citations 18

Authors

Zong-Lin Wu

Ya Yuan

He Geng

Shu-Jie Xia

Affiliations

Soon will be listed here.

Abstract

This study was designed to investigate the association between immune inflammation and androgen receptor (AR) expression in benign prostatic hyperplasia (BPH). We retrospectively analyzed 105 prostatectomy specimens. An immune inflammation score for each specimen was defined by combining three immunohistochemical markers (CD4, CD8 and CD20). The immunohistochemical markers were CD4 and CD8 for T lymphocytes, CD20 for B lymphocytes and AR antibody for the AR in BPH samples. Rates of CD4, CD8, CD20 and AR expression in BPH were 20 (19.0%), 21 (20.0%), 101 (96.2%) and 48 (45.7%), respectively. Total prostate volume (TPV) was higher in the immune inflammation group than in the non-immune inflammation group (62.7 ml vs. 49.2 ml, t=2.482, P<0.05). Patients in the immune inflammation group had a higher serum prostate-specific antigen (PSA) than those in the non-inflammation group (7.5 ng ml(-1 )vs. 5.4 ng ml(-1), t=2.771, P<0.05). Specifically, the immune inflammation group showed a higher rate of AR expression than the non-inflammation group (56.1% vs. 28.2%, χ(2)=7.665, P<0.05). Our study revealed a strong association between immune inflammation and TPV, serum PSA and AR expression in BPH tissue. Prostate hyperplasia caused by an immune inflammatory process may contribute to BPH progression over time. Therefore, the inflammatory response involved in BPH may be a prime therapeutic target.

Citing Articles

Intrinsic and extrinsic factors causing hyperplasia of the prostate.

Kyoda Y, Shibamori K, Shindo T, Maehana T, Hashimoto K, Kobayashi K Int J Urol. 2024; 31(7):705-717.

PMID: 38462732 PMC: 11524118. DOI: 10.1111/iju.15446.

Gender-affirming hormone therapy in transgender women and risk of prostate cancer: pathophysiological mechanisms and clinical implications.

Bologna E, Licari L, Franco A, Ditonno F, Leonardo C, De Nunzio C Prostate Cancer Prostatic Dis. 2024; 28(1):91-93.

PMID: 38297151 DOI: 10.1038/s41391-024-00796-1.

Phloretin in Benign Prostate Hyperplasia and Prostate Cancer: A Contemporary Systematic Review.

Yang C, Ou Y, Lin C, Lin Y, Tung M, Yu C Life (Basel). 2022; 12(7).

PMID: 35888117 PMC: 9322491. DOI: 10.3390/life12071029.

Immune Cell Proinflammatory Microenvironment and Androgen-Related Metabolic Regulation During Benign Prostatic Hyperplasia in Aging.

Cao D, Sun R, Peng L, Li J, Huang Y, Chen Z Front Immunol. 2022; 13:842008.

PMID: 35386711 PMC: 8977548. DOI: 10.3389/fimmu.2022.842008.

Review of the Roles and Interaction of Androgen and Inflammation in Benign Prostatic Hyperplasia.

Tong Y, Zhou R Mediators Inflamm. 2020; 2020:7958316.

PMID: 33192175 PMC: 7641707. DOI: 10.1155/2020/7958316.

References

Roehrborn C . Pathology of benign prostatic hyperplasia. Int J Impot Res. 2008; 20 Suppl 3:S11-8. DOI: 10.1038/ijir.2008.55. View

Lin D, Whitney M, Yao Z, Keller E . Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. Clin Cancer Res. 2001; 7(6):1773-81. View

Xia S, Xu C, Tang X, Wang W, Du D . Apoptosis and hormonal milieu in ductal system of normal prostate and benign prostatic hyperplasia. Asian J Androl. 2001; 3(2):131-4. View

Xia S, Xu X, Xu C, Tang X . Characteristic pattern of human prostatic growth with age. Asian J Androl. 2003; 4(4):269-71. View

Fibbi B, Penna G, Morelli A, Adorini L, Maggi M . Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl. 2009; 33(3):475-88. DOI: 10.1111/j.1365-2605.2009.00972.x. View

Bushman W . Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am. 2009; 36(4):403-15, v. DOI: 10.1016/j.ucl.2009.07.003. View

McConnell J, Roehrborn C, Bautista O, Andriole Jr G, Dixon C, Kusek J . The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003; 349(25):2387-98. DOI: 10.1056/NEJMoa030656. View

Begley L, Kasina S, Macdonald J, Macoska J . The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine. 2008; 43(2):194-9. PMC: 2538565. DOI: 10.1016/j.cyto.2008.05.012. View

Li J, Al-Azzawi F . Mechanism of androgen receptor action. Maturitas. 2009; 63(2):142-8. DOI: 10.1016/j.maturitas.2009.03.008. View

10.

Kramer G, Steiner G, Handisurya A, Stix U, Haitel A, Knerer B . Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate. 2002; 52(1):43-58. DOI: 10.1002/pros.10084. View

11.

Xia S, Hao G, Tang X . Androgen receptor isoforms in human and rat prostate. Asian J Androl. 2001; 2(4):307-10. View

12.

Kramer G, Marberger M . Could inflammation be a key component in the progression of benign prostatic hyperplasia?. Curr Opin Urol. 2005; 16(1):25-9. View

13.

Theyer G, Kramer G, Assmann I, Sherwood E, Preinfalk W, Marberger M . Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest. 1992; 66(1):96-107. View

14.

Sciarra A, Mariotti G, Salciccia S, Autran Gomez A, Monti S, Toscano V . Prostate growth and inflammation. J Steroid Biochem Mol Biol. 2007; 108(3-5):254-60. DOI: 10.1016/j.jsbmb.2007.09.013. View

15.

Zhu Y, Imperato-McGinley J . 5alpha-reductase isozymes and androgen actions in the prostate. Ann N Y Acad Sci. 2009; 1155:43-56. DOI: 10.1111/j.1749-6632.2009.04115.x. View

16.

Sciarra A, Di Silverio F, Salciccia S, Autran Gomez A, Gentilucci A, Gentile V . Inflammation and chronic prostatic diseases: evidence for a link?. Eur Urol. 2007; 52(4):964-72. DOI: 10.1016/j.eururo.2007.06.038. View

17.

Robert G, Descazeaud A, Nicolaiew N, Terry S, Sirab N, Vacherot F . Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate. 2009; 69(16):1774-80. PMC: 2833181. DOI: 10.1002/pros.21027. View

18.

Zhou Y, Xiao X, Chen L, Yang R, Shi J, Du X . Proliferation and phenotypic changes of stromal cells in response to varying estrogen/androgen levels in castrated rats. Asian J Androl. 2009; 11(4):451-9. PMC: 3735307. DOI: 10.1038/aja.2009.28. View

19.

St Sauver J, Jacobsen S . Inflammatory Mechanisms Associated with Prostatic Inflammation and Lower Urinary Tract Symptoms. Curr Prostate Rep. 2011; 6(2):67-73. PMC: 2757322. DOI: 10.1007/s11918-008-0011-5. View

20.

Nickel J, Roehrborn C, OLeary M, Bostwick D, Somerville M, Rittmaster R . The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol. 2007; 54(6):1379-84. PMC: 2643127. DOI: 10.1016/j.eururo.2007.11.026. View